In a recent study we showed (Gennari et al., 2012) a marked increase in circulating sclerostin levels in T2DM patients, with mean sclerostin concentrations>2-fold higher than in age- and sex-matched controls; this increase could represent a possible cause of reduced bone formation and of impaired bone quality observed in T2DM. Here, SOST is linked to type 2 diabetes mellitus.